Results 1 to 10 of about 152,498 (307)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

OncoTarget, 2014
There is an unmet need to develop new, more effective and safe therapies for the aggressive forms of triple negative breast cancers (TNBCs). While up to 20% of women under 50 years of age with TNBC harbor germline mutations in BRCA1, and these tumors are
Kyungsoo Ha, W. Fiskus, D. Choi, Srividya Bhaskara, L. Cerchietti, Santhana G. T. Devaraj, Bhavin Shah, Sunil Sharma, Jenny C. Chang, A. Melnick, S. Hiebert, K. Bhalla   +11 more
semanticscholar   +1 more source

In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Cancer is responsible for high morbidity and mortality globally. Because the overexpression of histone deacetylases (HDACs) is one of the molecular mechanisms associated with the development and progression of some diseases such as cancer ...
Kayode Adewole, Adebayo Ishola, Ige Olaoye   +2 more
doaj   +1 more source

Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights

Pharmacology and Therapeutics, 2014
Initially regarded as “epigenetic modifiers” acting predominantly through chromatin remodeling via histone acetylation, HDACIs, alternatively referred to as lysine deacetylase or simply deacetylase inhibitors, have since been recognized to exert multiple
P. Bose, Yun Dai, S. Grant
semanticscholar   +1 more source

Advances in non-Hydroxamate based Histone Deacetylase Inhibitors as Anticancer Agents [PDF]

Archives of Pharmaceutical Sciences Ain Shams University
The carcinogenesis process includes several epigenetic modifications that mainly target the silencing of tumor suppressor genes (TS genes) including ribonucleic acid (RNA) editing, deoxyribonucleic acid (DNA) hypermethylation and histone modification,
Nadine W. Nabiha, Maiy Y. Jaballahb, Rabah A.T. Serya, Khaled A.M. Abouzid   +3 more
doaj   +1 more source

The Potential Role of Epigenetic Drugs in the Treatment of Anxiety Disorders

Neuropsychiatric Disease and Treatment, 2020
Jacob Peedicayil Department of Pharmacology & Clinical Pharmacology, Christian Medical College, Vellore, IndiaCorrespondence: Jacob PeedicayilDepartment of Pharmacology & Clinical Pharmacology, Christian Medical College, Vellore, IndiaTel/Fax +91-
Peedicayil J
doaj  

Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

Haematologica, 2008
LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.
A. Kalff, J. Shortt, J. Farr, R. McLennan, A. Lui, J. Scott, A. Spencer   +6 more
doaj   +1 more source

Box–Behnken Assisted HPLC Development of Simultaneous Determination of Doxorubicin and Vorinostat Encapsulated into Polymeric Nanoparticles

Medical Sciences Forum, 2022
The objects of the present study are nanoparticles (NPs) based on a copolymer of lactic and glycolic acids (PLGA), loaded with the anticancer drug doxorubicin (DOX-NP) and histone deacetylase inhibitor vorinostat (SAHA-NP) and developed for breast cancer
Maria Sokol, Ivan Gulyaev, Mariia Mollaeva, Sergey Kuznetsov, Vladimir Zenin, Maksim Klimenko, Nikita Yabbarov, Margarita Chirkina, Elena Nikolskaya   +8 more
doaj   +1 more source

MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAFV600E: An In Vitro Study

Molecular Therapy: Oncolytics, 2019
Clinical efficacy of redifferentiation therapy with histone deacetylase inhibitor (HDACi) for lethal radioiodine-refractory papillary thyroid cancer (RR-PTC) is urgently needed to be improved.
Hao Fu, Lingxiao Cheng, Yuchen Jin, Lin Cheng, Min Liu, Libo Chen   +5 more
doaj   +1 more source

Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 2021
In discovery of HDAC inhibitors (HDACIs) with improved anticancer potency, structural modification was performed on the previous derived indole-3-butyric acid derivative.
Yiming Chen, Lihui Zhang, Lin Zhang, Qixiao Jiang, Lei Zhang   +4 more
doaj   +1 more source

The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus

Cells, 2021
Diabetes mellitus (DM) is one of the principal manifestations of metabolic syndrome and its prevalence with modern lifestyle is increasing incessantly.
Saikat Dewanjee, Jayalakshmi Vallamkondu, Rajkumar Singh Kalra, Pratik Chakraborty, Moumita Gangopadhyay, Ranabir Sahu, Vijaykrishna Medala, Albin John, P. Hemachandra Reddy, Vincenzo De Feo, Ramesh Kandimalla   +10 more
doaj   +1 more source